Skip to Content

Toradol IV / IM (ketorolac) Disease Interactions

There are 12 disease interactions with Toradol IV / IM (ketorolac):

Major

Ketorolac (Includes Toradol IV/IM) ↔ Gi Toxicity

Severe Potential Hazard, High plausibility

Applies to: Duodenitis/Gastritis, Gastrointestinal Hemorrhage, Gastrointestinal Perforation, History - Peptic Ulcer, Peptic Ulcer, Alcoholism, Colitis/Enteritis (Noninfectious), Colonic Ulceration

The use of ketorolac is contraindicated in patients with active peptic ulcers, recent gastrointestinal bleeding or perforation, or a history of peptic ulcer disease or gastrointestinal bleeding. Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID). NSAIDs can cause gastrointestinal mucosal damage, the risk of which appears to be related to both dosage and duration of therapy. Serious GI toxicity such as bleeding, ulceration and perforation can occur at any time, with or without warning symptoms, in patients treated with ketorolac. Therapy with ketorolac should be considered and administered cautiously in patients with a history of GI inflammation or alcoholism, particularly if they are elderly and/or debilitated, since such patients may be more susceptible to the GI toxicity of NSAIDs and seem to tolerate ulceration and bleeding less well than other individuals. Close monitoring for toxicity is recommended during ketorolac therapy, which should be limited to 5 days regardless of the route of administration.

References

  1. Fuller DK, Kalekas PJ "Ketorolac and gastrointestinal ulceration." Ann Pharmacother 27 (1993): 978-9
  2. Estes LL, Fuhs DW, Heaton AH, Butwinick CS "Gastric ulcer perforation associated with the use of injectable ketorolac." Ann Pharmacother 27 (1993): 42-3
  3. Litvak KM, McEvoy GK "Ketorolac, an injectable nonnarcotic analgesic." Clin Pharm 9 (1990): 921-35
  4. Wolfe PA, Polhamus CD, Kubik C, Robinson AB, Clement DJ "Giant duodenal ulcers associated with the postoperative use of ketorolac: report of three cases." Am J Gastroenterol 89 (1994): 1110-1
  5. Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
  6. Maliekal J, Elboim CM "Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly." Ann Pharmacother 29 (1995): 698-701
  7. Quigley EMM, Donovan JP, Livingston WC "Ketorolac-related giant gastric ulcers." Am J Gastroenterol 89 (1994): 631-2
  8. Wiedrick JE, Friesen EG, Garton AM, Otten NH "Upper gastrointestinal bleeding associated with oral ketorolac therapy." Ann Pharmacother 28 (1994): 1109
  9. Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6
  10. Strom BL, Berlin JA, Kinman JL "Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study." JAMA 275 (1996): 376-82
  11. Buckley MM, Brogden RN "Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 39 (1990): 86-109
  12. "Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
  13. Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8
View all 13 references
Major

Ketorolac (Includes Toradol IV/IM) ↔ Platelet Aggregation Inhibition

Severe Potential Hazard, Moderate plausibility

Applies to: Bleeding, Coagulation Defect, Thrombocytopathy, Thrombocytopenia, Vitamin K Deficiency

The use of ketorolac is considered by the manufacturer to be contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or a high risk of bleeding. Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID). NSAIDs reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities. Thrombocytopenia has also been reported rarely during NSAID use. Therapy with NSAIDs, including ketorolac, should be administered cautiously in patients with significant active bleeding.

References

  1. "Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
  2. Thwaites BK, Nigus DB, Bouska GW, Mongan PD, Ayala EF, Merrill GA "Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia." Anesth Analg 82 (1996): 1176-81
  3. Strom BL, Berlin JA, Kinman JL "Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study." JAMA 275 (1996): 376-82
  4. Litvak KM, McEvoy GK "Ketorolac, an injectable nonnarcotic analgesic." Clin Pharm 9 (1990): 921-35
  5. Concannon MJ, Meng L, Welsh CF, Puckett CL "Inhibition of perioperative platelet aggregation using toradol (ketorolac)." Ann Plast Surg 30 (1993): 264-6
View all 5 references
Major

Ketorolac (Includes Toradol IV/IM) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure, Dehydration, Renal Dysfunction, Hyponatremia

The use of ketorolac is contraindicated in patients with advanced renal impairment or increased risk for renal failure due to volume depletion. Ketorolac is a potent nonsteroidal anti-inflammatory drug (NSAID). The use of NSAIDs may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure. In patients with prerenal conditions whose renal perfusion may be dependent on the function of renal prostaglandins, NSAIDs may precipitate overt renal decompensation via a dose-related inhibition of prostaglandin synthesis. Patients at greatest risk for this reaction include geriatric patients and those with impaired renal function, heart failure, liver dysfunction, or substantial volume and/or sodium depletion (e.g., due to diuretics). Therapy with ketorolac should be administered cautiously in such patients, and hypovolemia and hyponatremia should be corrected prior to initiating treatment. Clinical monitoring of renal function is recommended during therapy. If renal function declines or renal failure occurs, prompt discontinuation of ketorolac therapy will usually lead to recovery to the pretreatment state. Since ketorolac and its metabolites are eliminated by the kidney, a reduction to half the normal dosage with a maximum of 60 mg/day is recommended in patients with moderately impaired renal function to avoid drug accumulation.

References

  1. Brocks DR, Jamali F "Clinical pharmacokinetics of ketorolac tromethamine." Clin Pharmacokinet 23 (1992): 415-27
  2. Quan DJ, Kayser SR "Ketorolac induced acute renal failure following a single dose." J Toxicol Clin Toxicol 32 (1994): 305-9
  3. Buller GK, Perazella MA "Acute renal failure and ketorolac." Ann Intern Med 127 (1997): 493
  4. Litvak KM, McEvoy GK "Ketorolac, an injectable nonnarcotic analgesic." Clin Pharm 9 (1990): 921-35
  5. Feldman HI, Kinman JL, Berlin JA, et al. "Parenteral ketorolac: the risk for acute renal failure." Ann Intern Med 126 (1997): 193-9
  6. Jung D, Mroszczak E, Bynum L "Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration." Eur J Clin Pharmacol 35 (1988): 423-5
  7. Pearce CJ, Gonzalez FM, Wallin JD "Renal failure and hyperkalemia associated with ketorolac tromethamine." Arch Intern Med 153 (1993): 1000-2
  8. Aitken HA, Burns JW, McArdle CS, Kenny GNC "Effects of ketorolac trometamol on renal function." Br J Anaesth 68 (1992): 481-5
  9. Perneger TV, Whelton PK, Klag MJ "Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs." N Engl J Med 331 (1994): 1675-9
  10. Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
  11. Fong J, Gora ML "Reversible renal insufficiency following ketorolac therapy." Ann Pharmacother 27 (1993): 510-2
  12. Haragsim L, Dalal R, Bagga H, Bastani B "Ketorolac-induced acute renal failure and hyperkalemia: report of three cases." Am J Kidney Dis 24 (1994): 578-80
  13. "Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
  14. Jallad NS, Garg DC, Martinez JJ, Mroszczak EJ, Weidler DJ "Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly." J Clin Pharmacol 30 (1990): 76-81
  15. Feldman HI, Kinman JL, Strom BL "Acute renal failure and ketorolac." Ann Intern Med 127 (1997): 493-4
  16. Myles PS, Power I "Does ketorolac cause postoperative renal failure: how do we assess the evidence?" Br J Anaesth 80 (1998): 420-1
  17. Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans." Drug Metab Dispos 15 (1987): 618-26
  18. Boras-Uber LA, Brackett NC Jr "Ketorolac-induced acute renal failure." Am J Med 92 (1992): 450-2
  19. Jung D, Mroszczak EJ, Wu A, Ling TL, Sevelius H, Bynum L "Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine." Pharm Res 6 (1989): 62-5
  20. Kelley M, Bastani B "Ketorolac-induced acute renal failure and hyperkalemia." Clin Nephrol 44 (1995): 276-7
  21. Martinez JJ, Garg DC, Pages LJ, et al "Single dose pharmacokinetics of ketorolac in healthy young and renal impaired subjects." J Clin Pharmacol 27 (1987): 722
  22. Buck ML, Norwood VF "Ketorolac-induced acute renal failure in a previously healthy adolescent." Pediatrics 98 (1996): 294-6
View all 22 references
Major

Nsaids (Includes Toradol IV/IM) ↔ Asthma

Severe Potential Hazard, High plausibility

Applies to: Asthma

Approximately 10% of patients with asthma may have aspirin-sensitive asthma, characterized by nasal polyposis, pansinusitis, eosinophilia, and precipitation of asthma and rhinitis attacks after ingestion of aspirin. The use of aspirin in these patients has been associated with severe bronchospasm and fatal anaphylactoid reactions. Since cross-sensitivity has been noted between aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), therapy with any NSAID should be avoided in asthmatic patients with a history of aspirin or other NSAID sensitivity, and administered cautiously in all patients with preexisting asthma. Prior to initiating therapy with NSAIDs, patients should be questioned about previous allergic-type reactions to these agents. Salicylate salts, salsalate, salicylamide, and acetaminophen may be appropriate alternatives in patients with a history of NSAID-induced bronchospasm, since cross-sensitivity to these agents appears to be low. However, cross-sensitivity has been demonstrated occasionally with high dosages of these agents (e.g., acetaminophen >= 1000 mg), thus it may be appropriate to initiate therapy with low dosages and increase gradually. There is some evidence suggesting that COX-2 inhibitors may be safely used in patients with aspirin-sensitive asthma, although the labeling for these products contraindicate such use. If necessary, aspirin desensitization may also be attempted in some patients under medical surveillance.

References

  1. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  4. Stevenson DD, Hougham AJ, Schrank PJ, Goldlust MB, Wilson RR "Salsalate cross-sensitivity in aspirin-sensitive patients with asthma." J Allergy Clin Immunol 86 (1990): 749-58
  5. "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  6. Stevenson DD, Simon RA "Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma." J Allerg Clin Immunol 108 (2001): 47-51
  7. Lewis RV "Severe asthma after naproxen." Lancet 05/30/87 (1987): 1270
  8. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  9. "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  10. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  11. Settipane RA, Stevenson DD "Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma." J Allergy Clin Immunol 84 (1989): 26-33
  12. Szczeklik A, Stevenson DD "Aspirin-induced asthma: Advances in pathogenesis and management." J Allerg Clin Immunol 104 (1999): 5-13
  13. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  14. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  15. Schreuder G "Ketoprofen: possible idiosyncratic acute bronchospasm." Med J Aust 152 (1990): 332-3
  16. Nasser SMS, Lee TH "Aspirin-induced early and late asthmatic responses." Clin Exp Allergy 25 (1995): 1-3
  17. Chan TY "Severe asthma attacks precipitated by NSAIDs." Ann Pharmacother 29 (1995): 199
  18. Lee TH "Mechanism of bronchospasm in aspirin-sensitive asthma." Am Rev Respir Dis 148 (1993): 1442-3
  19. Carmona MJ, Blanca M, Garcia A, Fernandez S, Burgos F, Miranda A, Vega JM, Garcia J "Intolerance to piroxicam in patients with adverse reactions to nonsteroidal antiinflammatory drugs." J Allergy Clin Immunol 90 (1992): 873-9
  20. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM "The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin." Am Rev Respir Dis 148 (1993): 1447-51
  21. Haddow GR, Riley E, Isaacs R, McSharry R "Ketorolac, nasal polyposis, and bronchial asthma: a cause for concern." Anesth Analg 76 (1993): 420-2
  22. "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  23. Cohen RD, Bateman ED, Potgieter PD "Near-fatal bronchospasm in an asthmatic patient following ingestion of flurbiprofen. A case report." S Afr Med J 61 (1982): 803
  24. Shapiro N "Acute angioedema after ketorolac ingestion - report of case." J Oral Maxillofac Surg 52 (1994): 626-7
  25. Ayres JG, Fleming DM, Whittington RM "Asthma death due to ibuprofen." Lancet 05/09/87 (1987): 1082
  26. "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  27. Salberg DJ, Simon MR "Severe asthma induced by naproxen: a case report and review of the literature." Ann Allergy 45 (1980): 372-5
  28. "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
  29. Lee TH "Mechanism of aspirin sensitivity." Am Rev Respir Dis 145 (1992): s34-6
  30. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  31. "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  32. "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  33. Woessner KM, Simon RA, Stevenson DD "The safety of celecoxib in patients with aspirin-sensitive asthma." Arthritis Rheum 46 (2002): 2201-6
  34. Zikowski D, Hord AH, Haddox JD, Glascock J "Ketorolac-induced bronchospasm." Anesth Analg 76 (1993): 417-9
  35. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  36. Dahlen B, Szczeklik A, Murray HH "Celecoxib in patients with asthma and aspirin intolerance." N Engl J Med 344 (2000): 142
  37. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  38. "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
View all 38 references
Major

Nsaids (Includes Toradol IV/IM) ↔ Fluid Retention

Severe Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure, Hypertension, Fluid Retention

Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

References

  1. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A "NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics." Arch Intern Med 158 (1998): 1108-12
  2. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  3. Agnholt J, Andreasen F "The effect of ibuprofen therapy on water and electrolyte balance." Acta Med Scand 212 (1982): 65-9
  4. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  5. Johnson AG, Nguyen TV, Day RO "Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis." Ann Intern Med 121 (1994): 289-300
  6. "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  7. Lewis RV, Toner JM, Jackson PR, Ramsay LE "Effects of indomethacin and sulindac on blood pressure of hypertensive patients." Br Med J 292 (1986): 934-5
  8. "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  9. "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  10. "Product Information. Anaprox (naproxen)." Roche Laboratories, Nutley, NJ.
  11. "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  12. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  13. Van Den Ouweland FA, Gribnau FW, Meyboom RH "Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly." Age Ageing 17 (1988): 8-16
  14. Gurwitz JH, Everitt DE, Monane M, et al "The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons." J Gerontol A Biol Sci Med Sci 51 (1996): m74-9
  15. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  16. "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  17. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  18. Willkens RF "Worldwide clinical safety experience with diclofenac." Semin Arthritis Rheum 2 Suppl 1 (1985): 105-10
  19. "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  20. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  21. Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
  22. Petersson I, Nilsson G, Hansson B-G, Hedner T "Water intoxication associated with non-steroidal anti-inflammatory drug therapy." Acta Med Scand 221 (1987): 221-3
  23. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  24. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  25. "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  26. Easton PA, Koval A "Hypertensive reaction with sulindac." Can Med Assoc J 122 (1980): 1273-4
  27. Heynen G "Toleration and safety of piroxicam." Eur J Rheumatol Inflamm 8 (1987): 86-93
  28. Buckley MM, Brogden RN "Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 39 (1990): 86-109
  29. "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
View all 29 references
Major

Nsaids (Includes Toradol IV/IM) ↔ Rash

Severe Potential Hazard, High plausibility

Applies to: Dermatitis - Drug-Induced

Severe, potentially fatal dermatologic reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and other exfoliative dermatitis have been associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). These events may occur without warning. Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of rash, blisters, fever, itching, or any other sign of hypersensitivity.

References

  1. "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  3. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  4. "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  5. "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  6. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  7. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  8. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  9. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  10. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  11. "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  12. "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  13. "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  14. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  15. Friedman B, Orlet HK, Still JM, Law E "Toxic epidermal necrolysis due to administration of celecoxib (Celebrex)." South Med J 95 (2002): 1213-4
  16. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
View all 16 references
Major

Nsaids (Includes Toradol IV/IM) ↔ Thrombosis

Severe Potential Hazard, High plausibility

Applies to: Cerebrovascular Insufficiency, History - Cerebrovascular Disease, History - Myocardial Infarction, Ischemic Heart Disease

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with an increased risk of cardiovascular thrombotic events such as myocardial infarction and stroke, which can be fatal. The risk may increase with duration of use. Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to three years duration have supported this association. Although not all NSAIDs have been studied, investigators believe it may be a class effect, and that the risk may be similar for all NSAIDs, both COX-2 selective and nonselective. Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease. Patients should be treated with the lowest effective dosage for the shortest duration necessary. Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection. However, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious GI events is increased. Patients should be advised to promptly seek medical attention if they experience symptoms that could indicate a cardiovascular thrombotic event such as chest pain, shortness of breath, weakness, and slurring of speech.

NSAIDs are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Two large clinical trials of a COX-2 inhibitor for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.

References

  1. Fitzgerald GA, Patrono C "The coxibs, selective inhibitors of cyclooxsygenase-2." N Engl J Med 345 (2001): 433-42
  2. "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  3. Marcus AJ, Broekman MJ, Pinsky DJ "COX inhibitors and thromboregulation." N Engl J Med 347 (2002): 1025-6
  4. Mukherjee D, Nissen SE, Topol EJ "Risk of cardiovascular events associated with selective COX-2 inhibitors." JAMA 286 (2001): 954-9
  5. Bombardier C, Laine L, Reicin A, et al. "Comparison of upper gastrointestinal toxicity of refecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group." N Engl J Med 343 (2000): 1520-8
  6. Silverstein FE, Faich G, Goldstein JL, et al. "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthtitis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial." JAMA 284 (2000): 1247-55
View all 6 references
Moderate

Nsaids (Includes Toradol IV/IM) ↔ Anemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Anemia, Bleeding

Dose-dependent decreases in serum hemoglobin and hematocrit have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). Anemia has been reported occasionally. The mechanism may involve NSAID-induced fluid retention or gastrointestinal blood loss, or an incompletely described effect on erythropoiesis. The decreases in hemoglobin concentration tend to be slight with average doses but may exceed 1 g/dL when large doses are given, such as those used to treat osteoarthritis or rheumatoid arthritis. Although these effects are generally not clinically important in otherwise healthy individuals, they may be relevant in patients with preexisting anemia or substantial blood loss. Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia. Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.

References

  1. "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  2. Salom IL, Jacob G, Jallad N, Perdomo CA, Mullane JF, Weidler D "Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males." J Clin Pharmacol 24 (1984): 240-6
  3. "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
  4. Squires JE, Mintz PD, Clark S "Tolmetin-induced hemolysis." Transfusion 25 (1985): 410-3
  5. Kornberg A, Rachmilewitz EA "Aplastic anemia after prolonged ingestion of indomethacin." Acta Haematol 67 (1982): 136-8
  6. Bennett L, Schlossman R, Rosenthal J, et al "Aplastic anemia and sulindac." Ann Intern Med 92 (1980): 874
  7. Johnson FP Jr, Hamilton HE, Liesch MR "Immune hemolytic anemia associated with sulindac." Arch Intern Med 145 (1985): 1515-6
  8. Arnold R, Heimpel H "Aplastic anaemia after naproxen?" Lancet 02/09/80 (1980): 321
  9. Catalano MA "Worldwide safety experience with diclofenac." Am J Med 80 (1986): 81-7
  10. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  11. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  12. Angeles ML, Reid ME, Yacob UA, Cash KL, Fetten JV "Sulindac-induced immune hemolytic anemia." Transfusion 34 (1994): 255-8
  13. "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  14. Randi ML, Tison T, Luzzatto G "Haemolytic uraemic syndrome during treatment with ketorolac trometamol." BMJ 306 (1993): 186
  15. "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  16. Bernhard GC "Worldwide safety experience with nabumetone." J Rheumatol 19 (1992): 48-57
  17. Gerber D "Adverse reactions of piroxicam." Drug Intell Clin Pharm 21 (1987): 707-10
  18. Reitz CL, Bottomley SS "Pure red cell aplasia associated with fenoprofen." Am J Med Sci 287 (1984): 62-3
  19. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  20. Eustace S, O'Neill T, McHale S, Molony J "Fatal aplastic anaemia following prolonged diclofenac use in an elderly patient." Ir J Med Sci 158 (1989): 217
  21. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  22. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  23. "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  24. Sanz MA, Martinez JA, Gomis F, Garcia-Borras JJ "Sulindac-induced bone marrow toxicity." Lancet 2 (1980): 802-3
  25. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  26. Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
  27. "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  28. Salama A, Gottsche B, Mueller-Eckhardt C "Autoantibodies and drug- or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis." Br J Haematol 77 (1991): 546-9
  29. "Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.
  30. Sanada M, Takai K "Aplastic anaemia associated with piroxicam." Br J Haematol 77 (1991): 256-7
  31. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  32. Andrews R, Russell N "Aplastic anaemia associated with a non-steroidal anti-inflammatory drug: relapse after exposure to another such drug." Br Med J 301 (1990): 38
  33. Schattenkirchner M "An updated safety profile of etodolac in several thousand patients." Eur J Rheumatol Inflamm 10 (1990): 56-65
  34. Lopez A, Linares M, Sanchez H, Blanquer A "Autoimmune hemolytic anemia induced by diclofenac." Ann Pharmacother 29 (1995): 787
  35. Miller JL "Marrow aplasia and sulindac." Ann Intern Med 92 (1980): 129
  36. Ashraf M, Pearson RM, Winfield DA "Aplastic anaemia associated with fenoprofen." Br Med J 284 (1982): 1301-2
  37. Lee SH, Fawcett V, Preece JM "Aplastic anaemia associated with piroxicam." Lancet 1 (1982): 1186
  38. Hughes JA, Sudell W "Hemolytic anemia associated with naproxen." Arthritis Rheum 26 (1983): 1054
  39. Lussier A, LeBel E "Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone." Am J Med 83 (1987): 15-8
  40. "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  41. "Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
  42. Kramer MR, Levene C, Hershko C "Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy." Scand J Haematol 36 (1986): 118-20
  43. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  44. McNeil P, MacKenzie I, Manoharan A "Naproxen-associated aplastic anaemia." Med J Aust 145 (1986): 53-5
  45. Schattner A, Shtalrid M, Levy R, Berrebi A "Fatal aplastic anemia due to indomethacin: lymphocyte transformation tests in vitro." Isr J Med Sci 17 (1981): 433-6
  46. Green D, Davies RO, Holmes GI et al "Effects of diflunisal on platelet function and fecal blood loss." Pharmacotherapy 3 (1983): s65-9
  47. "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  48. van Dijk BA, Rico PB, Hoitsma A, Kunst VA "Immune hemolytic anemia associated with tolmetin and suprofen." Transfusion 29 (1989): 638-41
  49. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
View all 49 references
Moderate

Nsaids (Includes Toradol IV/IM) ↔ Heart Failure

Moderate Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure

Fluid retention and edema have been observed in patients treated with NSAIDs, including some topical formulations. These drugs should be used with caution in patients with fluid retention or heart failure.

Moderate

Nsaids (Includes Toradol IV/IM) ↔ Hepatotoxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Borderline elevations of serum transaminases, LDH, and alkaline phosphatase have been reported in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). These abnormalities may progress, remain unchanged, or regress with continuing therapy. Notable liver enzyme elevations exceeding 3 times the upper limit of normal have been reported in approximately 1% of patients in clinical trials. In addition, rare cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice and fatal fulminant hepatitis, have been reported. Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease. Periodic monitoring of liver function is recommended during prolonged therapy. NSAIDs are also highly protein-bound and some are extensively metabolized by the liver. Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment. A dosage reduction may be required in some cases.

References

  1. "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. Selley ML, Madsen BW, Thomas J "Protein binding of tolmetin." Clin Pharmacol Ther 24 (1978): 694-705
  3. Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans." Drug Metab Dispos 15 (1987): 618-26
  4. Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR "Metabolism of nabumetone (BRL 14777) by various species including man." Xenobiotica 14 (1984): 327-37
  5. Dhand AK, LaBrecque DR, Metzger J "Sulindac (clinoril) hepatitis." Gastroenterology 80 (1981): 585-6
  6. Whittaker SJ, Amar JN, Wanless IR, Heathcote J "Sulindac hepatotoxicity." Gut 23 (1982): 875-7
  7. Davies NM "Clinical pharmacokinetics of flurbiprofen and its enantiomers." Clin Pharmacokinet 28 (1995): 100-14
  8. Lockwood GF, Albert KS, Szpunar GJ, Wagner JG "Pharmacokinetics of ibuprofen in man III: plasma protein binding." J Pharmacokinet Biopharm 11 (1983): 469-82
  9. Reeve PA, Moshiri M, Bell GD "Pulmonary oedema, jaundice and renal impairment with naproxen." Br J Rheumatol 26 (1987): 70-1
  10. Knadler MP, Brater DC, Hall SD "Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status." J Pharmacol Exp Ther 249 (1989): 378-85
  11. Banks AT, Zimmerman HJ, Ishak KG, Harter JG "Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions." Hepatology 22 (1995): 820-7
  12. Homon CA, Fluck ER, Janssen FW, Ruelius HW "Protein binding and clearance of oxaprozin, a highly bound anti- inflammatory agent." Agents Actions 12 (1982): 211-5
  13. Hucker HB, Stauffer SC, White SD, et al "Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidenyl]-indene-3-acetic acid in the." Drug Metab Dispos 1 (1973): 721-36
  14. "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  15. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J "Diclofenac-associated hepatotoxicity." JAMA 264 (1990): 2660-2
  16. Hyneck ML, Smith PC, Munafo A, et al "Disposition and irreversible plasma protein binding of tolmetin in humans." Clin Pharmacol Ther 44 (1988): 107-14
  17. Breen EG, McNicholl J, Cosgrove E, McCabe J, Stevens FM "Fatal hepatitis associated with diclofenac." Gut 27 (1986): 1390-3
  18. Ramakrishna B, Viswanath N "Diclofenac-induced hepatitis - case report and literature review." Liver 14 (1994): 83-4
  19. Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilber J, Dvornik D, Cayen MN "Disposition and biotransformation of C-etodolac in man." Xenobiotica 16 (1986): 153-66
  20. Hyson CP, Kazakoff MA "A severe multisystem reaction to sulindac." Arch Intern Med 151 (1991): 387-8
  21. Riess W, Stierlin H, Degen P, et al "Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren." Scand J Rheumatol Suppl 22 (1978): 17-29
  22. Lewellen OR, Templeton R "The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50mg q.i.d.) with orudis." Scand J Rheumatol 14 (1976): 53-62
  23. Duggan DE, Hogans AF, Kwan KC, McMahon FG "The metabolism of indomethacin in man." J Pharmacol Exp Ther 181 (1972): 563-75
  24. Chamouard JM, Barre J, Urien S, Houin G, Tillement JP "Diclofenac binding to albumin and lipoproteins in human serum." Biochem Pharmacol 34 (1985): 1695-700
  25. Verbeeck RK, Richardson CJ, Blocka KL "Clinical pharmacokinetics of piroxicam." J Rheumatol 13 (1986): 789-96
  26. Scully LJ, Clarke D, Barr RJ "Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis." Dig Dis Sci 38 (1993): 744-51
  27. Bhogaraju A, Nazeer S, AlBaghdadi Y, Rahman M, Wrestler F, Patel N "Diclofenac-associated hepatitis." South Med J 92 (1999): 711-3
  28. Calvo MV, Dominguez-Gil A, Macias JG, Diez JL "Naproxen disposition in hepatic and biliary disorders." Int J Clin Pharmacol Ther Toxicol 18 (1980): 242-6
  29. Paterson D, Kerlin P, Walker N, et al "Piroxicam induced submassive necrosis of the liver." Gut 33 (1992): 1436-8
  30. "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  31. "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  32. Brocks DR, Jamali F "Clinical pharmacokinetics of ketorolac tromethamine." Clin Pharmacokinet 23 (1992): 415-27
  33. Purcell P, Henry D, Melville G "Diclofenac hepatitis." Gut 32 (1991): 1381-5
  34. Turner R "Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis." Semin Arthritis Rheum 17 (1988): 29-35
  35. Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
  36. "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  37. Alvan G, Orme M, Bertilsson L, et al "Pharmacokinetics of indomethacin." Clin Pharmacol Ther 18 (1975): 364-73
  38. Hepps KS, Maliha GM, Estrada R, Goodgame RW "Severe cholestatic jaundice associated with piroxicam." Gastroenterology 101 (1991): 1737-40
  39. "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  40. Planas R, De Leon R, Quer JC, Barranco C, Bruguera M, Gassull MA "Fatal submassive necrosis of the liver associated with piroxicam." Am J Gastroenterol 85 (1990): 468-70
  41. "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  42. Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
  43. Sherman KE, Jones C "Hepatotoxicity associated with piroxicam use." Gastroenterology 103 (1992): 354-5
  44. "Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.
  45. Victorino RM, Baptista A, Silveira JC, de Moura MC "Jaundice associated with naproxen." Postgrad Med J 56 (1980): 368-70
  46. Julh RP, Van Thiel DH, Dittert LW, et al "Ibuprofen and sulindac kinetics in alcoholic liver disease." Clin Pharmacol Ther 34 (1983): 104-9
  47. "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
  48. Catalano MA "Worldwide safety experience with diclofenac." Am J Med 80 (1986): 81-7
  49. Rubin A, Warrick P, Wolen RL, et al "Physiological disposition of fenoprofen in man III: metabolism and protein binding of fenoprofen." J Pharmacol Exp Ther 183 (1972): 449-57
  50. Jick H, Derby LE, Rodriguez LA, et al "Liver disease associated with diclofenac, naproxen, and piroxicam." Pharmacotherapy 12 (1992): 207-12
  51. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  52. Park GD, Spector R, Headstream T, Goldberg M "Serious adverse reactions associated with sulindac." Arch Intern Med 142 (1982): 1292-4
  53. Purdum PP, Shelden SL, Boyd JW, Shiffman ML "Oxaprozin-induced fulminant hepatitis." Ann Pharmacother 28 (1994): 1159-61
  54. Lee SM, O'Brien CJ, Williams R, Whitaker S, Gould SR "Subacute hepatic necrosis induced by piroxicam." Br Med J (Clin Res Ed) 293 (1986): 540-1
  55. Gallanosa AG, Spyker DA "Sulindac hepatotoxicity: a case report and review." Clin Toxicol 23 (1985): 205-38
  56. Cappell MS, Kozicky O, Competiello LS "Indomethacin-induced cholestasis." J Clin Gastroenterol 10 (1988): 445-7
  57. Brocks DR, Jamali F "Etodolac clinical pharmacokinetics." Clin Pharmacokinet 26 (1994): 259-74
  58. "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  59. Blouin R, Chaudhary I, Nishihara K, Cox S "The effects of liver and renal disease on stereoselective serum binding of flurbiprofen." Br J Clin Pharmacol 35 (1993): 62-4
  60. "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  61. Williams RL, Upton RA, Cello JP, et al "Naproxen disposition in patients with alcoholic cirrhosis." Eur J Clin Pharmacol 27 (1984): 291-6
  62. "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  63. Sallie RW, McKenzie T, Reed WD, Quinlan MF, Shilkin KB "Diclofenac hepatitis." Aust N Z J Med 21 (1991): 251-5
  64. Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW "Metabolism and kinetics of oxaprozin in normal subjects." Clin Pharmacol Ther 27 (1980): 352-62
  65. Helleberg L "Clinical pharmacokinetics of indomethacin." Clin Pharmacokinet 6 (1981): 245-58
  66. "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  67. "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  68. Selley ML, Glass J, Triggs EJ, Thomas J "Pharmacokinetic studies of tolmetin in man." Clin Pharmacol Ther 17 (1975): 599-605
  69. Hyneck ML "An overview of the clinical pharmacokinetics of nabumetone." J Rheumatol 19 (1992): 20-4
  70. "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  71. Daniele B, Pignata S, D'Agostino L, et al "Sulindac-induced severe hepatitis." Am J Gastroenterol 83 (1988): 1429-31
  72. Hvidberg E, Lausen HH, Jansen JA "Indomethacin: plasma concentrations and protein binding in man." Eur J Clin Pharmacol 4 (1972): 119-24
  73. Caballeria E, Masso RM, Arago JV, Sanchis A "Piroxicam hepatotoxicity." Am J Gastroenterol 85 (1990): 898-9
  74. Stierlin H, Faigle JW "Biotransformation of diclofenac sodium (Voltaren) in animals and man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile." Xenobiotica 9 (1979): 611-21
  75. Zimmerman HJ "Hepatic effects of oxaprozin." Semin Arthritis Rheum 15 (1986): 35-9
  76. "Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
  77. Richardson CJ, Blocka KL, Ross SG, Verbeeck RK "Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam." Eur J Clin Pharmacol 32 (1987): 89-91
  78. Wood LJ, Mundo F, Searle J, Powell LW "Sulindac hepatotoxicity: effects of acute and chronic exposure." Aust N Z J Med 15 (1985): 397-401
  79. Giroux Y, Moreau M, Kass TG "Cholestatic jaundice caused by sulindac." Can J Surg 25 (1982): 334-5
  80. Klein SM, Khan MA "Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy." J Rheumatol 10 (1983): 513-3
  81. Lasseter K, Shamblen E, Murdoch A, Marino M, Minor M, Kraml MJ "Pharmacokinetics of etodolac in patients with hepatic cirrhosis." J Clin Pharmacol 28 (1988): 933
  82. Gerber D "Adverse reactions of piroxicam." Drug Intell Clin Pharm 21 (1987): 707-10
  83. Macdonald JI, Wallace SM, Mahachai V, Verbeeck RK "Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis." Eur J Clin Pharmacol 42 (1992): 471-4
  84. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG "The pharmacokinetics of diclofenac sodium following intravenous and oral administration." Eur J Clin Pharmacol 16 (1979): 405-10
  85. Mabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ "Fulminant hepatic failure associated with etodolac use." Am J Gastroenterol 90 (1995): 659-61
  86. Pages LJ, Martinez JJ, Garg DC, et al "Pharmacokinetics of ketorolac tromethamine in hepatically impaired vs young healthy subjects." J Clin Pharmacol 27 (1987): 724
  87. O'Brien WM, Bagby GF "Rare adverse reactions to nonsteroidal antiinflammatory drugs." J Rheumatol 12 (1985): 562-7
  88. Maleev A, Vlahov V, Gruev I, Dierdorf D, Kostova N, Bacracheva N "Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone." Int J Clin Pharmacol Ther Toxicol 24 (1986): 425-9
  89. "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  90. Schattenkirchner M "An updated safety profile of etodolac in several thousand patients." Eur J Rheumatol Inflamm 10 (1990): 56-65
  91. "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  92. Stierlin H, Faigle JW, Sallmann A, et al "Biotransformationm of diclofenac sodium (Voltaren) in animal and in man. I. Isolation and identification of principal metabolites." Xenobiotica 9 (1979): 601-10
View all 92 references
Moderate

Nsaids (Includes Toradol IV/IM) ↔ Hyperkalemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperkalemia, Renal Dysfunction

Increase in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic- hypoaldosteronism state.

Moderate

Nsaids (Includes Toradol IV/IM) ↔ Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypertension

NSAIDs including topicals can lead to the onset of new hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. Blood pressure should be monitored closely during NSAID therapy and throughout the course of therapy.

Toradol IV / IM (ketorolac) drug Interactions

There are 467 drug interactions with Toradol IV / IM (ketorolac)

Toradol IV / IM (ketorolac) alcohol/food Interactions

There are 3 alcohol/food interactions with Toradol IV / IM (ketorolac)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide